MET/VEGFR2 inhibitor GSK1363089 (XL880)is an orally bioavailable
small molecule with potential antineoplastic activity. This compound
binds to and selectively inhibits hepatocyte growth factor receptor
c-MET and vascular endothelial growth factor receptor 2 (VEGFR2),
which may result in the inhibition of tumor angiogenesis, tumor cell
proliferation and metastasis.
Liu L, Greger J, Shi H, Liu Y, Greshock J,et al. Cancer Res. 2009 Sep 1;69
(17):6871-8. Epub 2009 Aug 11.